204 related articles for article (PubMed ID: 32039367)
1. HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.
Ferrando-Martinez S; Huang K; Bennett AS; Sterba P; Yu L; Suzich JA; Janssen HLA; Robbins SH
JHEP Rep; 2019 Sep; 1(3):170-178. PubMed ID: 32039367
[TBL] [Abstract][Full Text] [Related]
2. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T
J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436
[TBL] [Abstract][Full Text] [Related]
3. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
5. IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B.
Chua C; Salimzadeh L; Ma AT; Adeyi OA; Seo H; Boukhaled GM; Mehrotra A; Patel A; Ferrando-Martinez S; Robbins SH; La D; Wong D; Janssen HLA; Brooks DG; Feld JJ; Gehring AJ
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38055623
[TBL] [Abstract][Full Text] [Related]
6. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
Balsitis S; Gali V; Mason PJ; Chaniewski S; Levine SM; Wichroski MJ; Feulner M; Song Y; Granaldi K; Loy JK; Thompson CM; Lesniak JA; Brockus C; Kishnani N; Menne S; Cockett MI; Iyer R; Mason SW; Tenney DJ
PLoS One; 2018; 13(2):e0190058. PubMed ID: 29444087
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
9. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients.
Peng G; Li S; Wu W; Tan X; Chen Y; Chen Z
Mol Immunol; 2008 Feb; 45(4):963-70. PubMed ID: 17868872
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
11. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection.
Wang H; Luo H; Wan X; Fu X; Mao Q; Xiang X; Zhou Y; He W; Zhang J; Guo Y; Tan W; Deng G
J Hepatol; 2020 Jan; 72(1):45-56. PubMed ID: 31499130
[TBL] [Abstract][Full Text] [Related]
12. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.
Bengsch B; Martin B; Thimme R
J Hepatol; 2014 Dec; 61(6):1212-9. PubMed ID: 25016223
[TBL] [Abstract][Full Text] [Related]
13. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
14. [Hepatitis B e antigen from chronic hepatitis B patients induces Th1/Th2 cytokine imbalance in vitro].
Han YP; Li J; Jiang LF; Xu QQ; Liu B; Dong L; Chen N; Kong LH; Xie FR; Huang ZH
Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):584-9. PubMed ID: 24119737
[TBL] [Abstract][Full Text] [Related]
15. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
[TBL] [Abstract][Full Text] [Related]
16. [PD-L1 expression in circulating dendritic cells of patients with chronic hepatitis B].
Peng GP; Sun W; Wu W; Sun Z; Tan XF; Li SP; Chen Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 37(4):364-72. PubMed ID: 18705009
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus (HBV)-specific T-cell responses to recombinant HBV core protein in patients with normal liver function and co-infected with chronic HBV and human immunodeficiency virus 1 (HIV-1).
Zhang X; Xing H; Feng X; Zhang H; Wang Y; Yan H
Virol J; 2013 Jul; 10():232. PubMed ID: 23849342
[TBL] [Abstract][Full Text] [Related]
18. [Effect of tenofovir disoproxil fumarate antiviral therapy on virus-specific CD8+T Cells function in patients with chronic hepatitis B].
Duan SP; Zhu LH; Hou LJ; Wang HW; Zhu XW; Hao J
Zhonghua Gan Zang Bing Za Zhi; 2021 May; 29(5):421-426. PubMed ID: 34107578
[No Abstract] [Full Text] [Related]
19. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
